Clinical Trials Industry News More

  1. Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate In Metastatic Melanoma Patients In The New England Journal Of Medicine 8/27/2010
    Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients.
  2. Akebia Announces Initiation Of Phase 2a Clinical Study Of AKB-6548 7/22/2010
    Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has initiated dosing in patients for a phase 2a single dose clinical trial of AKB-6548, an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) in development for anemia.
  3. Pennington Biomedical Research Institute And Compellis Pharmaceuticals Complete Phase I Study Of Novel And Patented Obesity Therapy 7/22/2010
    Compellis Pharmaceuticals, Inc., an early-stage pharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today with its collaborator Pennington Biomedical Research Institute at Louisiana State University, that they have successfully completed a human Phase I pilot clinical trial.
  4. Tekmira's Partner Alnylam Initiates Dosing In A Phase 1 Clinical Trial Of ALN-TTR01 7/8/2010
    Tekmira Pharmaceuticals Corporation (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that one of the company's partners, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has initiated dosing in a Phase 1 human clinical trial of its product candidate ALN-TTR01.
  5. Infinity Initiates Second Clinical Trial Of IPI-493, Its Oral Hsp90 Chaperone Inhibitor 6/29/2010
    Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies.
  6. Avexa Halts HIV Drug Trials: The Future Decoded 5/12/2010
    Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.
  7. Prana To Commence Phase IIb Trial On PBT2 4/23/2010
    Prana Biotechnology recently announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer’s disease drug, PBT2, before the end of this year.
  8. UF-Led Effort Creates Virus Reference Standard That Can Improve Patient Safety In Clinical Trials 4/13/2010
    The use of viruses as vehicles for delivering genes to replace malfunctioning or missing ones holds promise for treating many disorders. Adeno-associated viruses are one type of vector being used increasingly in human gene therapy clinical trials and laboratory studies leading up to those trials.
  9. SciClone Announces Topline Results From Phase 2 Clinical Trial Of SCV-07 For Prevention Of Oral Mucositis 4/1/2010
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced topline results from the company's phase 2 clinical trial of SCV-07 for the prevention of severe oral mucositis (OM) (World Health Organization, WHO scale, grades 3 to 4) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
  10. AspenBio Completes Patient Enrollment Of AppyScore Clinical Trial To Support FDA 510(k) Submission 3/24/2010
    AspenBio Pharma, Inc. (NASDAQ: APPY) has completed patient enrollment for its AppyScore™ pivotal clinical trial designed to evaluate 800 patients suspected of having acute appendicitis. The study has now advanced to the data analysis phase.